Fibromyalgia
Drug research and approvals for fibromyalgia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 142 studies of fibromyalgia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 142
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 142 recruiting on ClinicalTrials.gov ↗- Light Bulb Stimuli to Reduce Chronic PainNCT07825792 · Not applicable · University of North Carolina, Chapel Hill · starts Nov 9, 2026
- PRL2019 in the Treatment of Juvenile FibromyalgiaNCT07738926 · Not applicable · Istituto Giannina Gaslini · starts Nov 2, 2026
- Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain SyndromeNCT07572994 · Not applicable · Cairo University · starts Nov 1, 2026
- Respiratory Function in Fibromiyalgia SyndromeNCT07913126 · Not reported · Karabuk University · starts Oct 25, 2026
- Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility StudyNCT07874217 · Not applicable · Oxford Brookes University · starts Oct 5, 2026
- Melatonin and Immunonutrition for Pain Relief in FibromyalgiaNCT07863232 · Not applicable · University of Thessaly · starts Oct 1, 2026
- Biopsychosocial Risk Influences on the Development and Generation of Early-Onset Chronic PainNCT07602595 · Not reported · Children's Hospital Medical Center, Cincinnati · starts Oct 1, 2026
- Mandala Coloring for Pain, Fatigue, and Sleep in Patients With FibromyalgiaNCT07733739 · Not applicable · Artvin Coruh University · starts Sep 22, 2026
- MDMA-assisted Therapy for FibromyalgiaNCT06066853 · Early Phase 1 · Spaulding Rehabilitation Hospital · starts Sep 15, 2026
- Effects of Box Breathing Exercise in Patients With FibromyalgiaNCT07722923 · Not applicable · Artvin Coruh University · starts Sep 14, 2026
Drug Pipeline
4 approved, 15 in phase 3, 26 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Pregabalin, Milnacipran, Duloxetine, Levomilnacipran
- Cyclobenzaprine
- Phase 3 Serotonin 2a (5-HT2a) receptor antagonist
- Esreboxetine
- Phase 3 Norepinephrine transporter inhibitor
- Mirogabalin
- Phase 3 Voltage-gated calcium channel alpha2/delta subunit 1 modulator
- Amitriptyline
- Phase 3 Serotonin transporter inhibitor
- Reboxetine
- Phase 3 Norepinephrine transporter inhibitor
- Oxybate
- Phase 3 GABA-B receptor agonist
- Gabapentin
- Phase 3 Voltage-gated calcium channel modulator
- Cannabidiol
- Phase 3 Cannabinoid CB1 receptor negative allosteric modulator
- Fluoxetine
- Phase 3 Serotonin transporter inhibitor
- Tramadol
- Phase 3 Mu opioid receptor agonist
- Lidocaine
- Phase 3 Sodium channel alpha subunit blocker
- Ketotifen
- Phase 3 Histamine H1 receptor antagonist
- Dolasetron
- Phase 3 Serotonin 3a (5-HT3a) receptor antagonist
- Memantine
- Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
- Erenumab
- Phase 3 Calcitonin gene-related peptide type 1 receptor antagonist
- Desvenlafaxine
- Phase 2 Serotonin transporter inhibitor
- Naltrexone
- Phase 2 Opioid receptors; mu/kappa/delta antagonist
- Dextromethorphan
- Phase 2 Sigma opioid receptor agonist
- Psilocybin
- Phase 2 Serotonin 2a (5-HT2a) receptor agonist
- Cannabinol
- Phase 2
- NYX-2925
- Phase 2
- Escitalopram
- Phase 2 Serotonin transporter inhibitor
- Metformin
- Phase 2 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Mirtazapine
- Phase 2 Serotonin 2a (5-HT2a) receptor antagonist
- Pyridostigmine
- Phase 2 Acetylcholinesterase inhibitor
- Ropinirole
- Phase 2 D2-like dopamine receptor agonist
- Droxidopa
- Phase 2 Adrenergic receptor agonist
- Carbidopa anhydrous
- Phase 2 DOPA decarboxylase inhibitor
- Cycloserine
- Phase 2 D-alanylalanine synthetase inhibitor
- Nabilone
- Phase 2 Cannabinoid CB1 receptor agonist
Showing the 30 furthest along of 49 in trials.
How Its Trials Ended
1,156 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 201 whose ending is known, 62% met their primary endpoint, 7% missed it and 30% stopped early.
- Completed, result not reported59952%
- Ongoing20818%
- Status unknown14813%
- Met its primary endpoint12511%
- Stopped: other or unclear393%
- Missed its primary endpoint151%
- Stopped: enrollment or feasibility61%
- Stopped: sponsor or business decision50%
- Stopped: funding50%
- Stopped: lack of efficacy40%
- Stopped: safety20%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Apr 5, 2022 | A randomized controlled trial of adjunctive d-cycloserine to intermittent theta-burst stimulation transcranial magnetic stimulation in fibromyalgiaCycloserine | University Of Calgary | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA